OptimizeRx (OptimizeRx) Additional Paid-In Capital : $190.79 Mil(As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx Additional Paid-In Capital?

OptimizeRx's quarterly additional paid-in capital increased from Jun. 2023 ($173.05 Mil) to Sep. 2023 ($176.21 Mil) and increased from Sep. 2023 ($176.21 Mil) to Dec. 2023 ($190.79 Mil).

OptimizeRx's annual additional paid-in capital increased from Dec. 2021 ($166.62 Mil) to Dec. 2022 ($172.79 Mil) and increased from Dec. 2022 ($172.79 Mil) to Dec. 2023 ($190.79 Mil).

OptimizeRx Additional Paid-In Capital Historical Data

The historical data trend for OptimizeRx's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptimizeRx Additional Paid-In Capital Chart

OptimizeRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

78.27

85.59

166.62

172.79

190.79

OptimizeRx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															172.79	177.04	173.05	176.21	190.79

OptimizeRx Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

OptimizeRx Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of OptimizeRx's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

OptimizeRx (OptimizeRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Water Street, Suite 200, Rochester, MI, USA, 48307

Website

https://www.optimizerx.com

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Executives

Marion Odence-ford	officer: General Counsel and CCO	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco	officer: Chief Commercial Officer	260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch	officer: Chief Product Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo	officer: Chief Executive Officer	600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro	officer: Chief Commercial Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos	director	C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh	officer: COO and CFO	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore	officer: President	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler	director, officer: SVP of Product & Strategy	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker	officer: Chief Financial Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman	officer: Chief Technology Officer	400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson	director	200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas	director	38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022